cysteamine bitartrate

cysteamine bitartrate

an anticysteine that reacts with cystine in the cell lysosomes to convert it to cysteine and a mixed disulfide compound, which can then exit the lysosome in patients with a metabolic defect causing cystinosis.
indications It is prescribed in the treatment of an inherited amino acid metabolic disease in which cysteine accumulates in the cells and can lead to the formation of crystals that can damage various organs, especially the kidneys (nephropathic cystinosis).
contraindications It should not be given to patients with allergy to cysteamine or penicillamine, depression, drowsiness, lethargy, neurological disorders, or diseases of the liver or digestive tract.
adverse effects The side effects most often reported include vomiting, diarrhea, constipation, appetite loss, nausea, headaches, convulsions, and seizures.
Mentioned in ?
References in periodicals archive ?
Pharmacokinetic evaluation showed that DR Cysteamine had a terminal half-life more than three times longer than the terminal half-life of immediate-release cysteamine bitartrate capsules.
Raptor" or the "Company") (Nasdaq: RPTPD), announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.
Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease.
Raptor's Chief Medical Officer, will present an update on the Company's ongoing Phase 2b study of delayed-release cysteamine bitartrate ("DR Cysteamine") for the potential treatment of cystinosis, and its plans for further clinical development of the product candidate, at the Cystinosis Research Network ("CRN") Family Conference, taking place July 16-18, 2009 in Atlanta, GA.
Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the completion of patient enrollment in its Phase 2a open-label clinical trial to evaluate cysteamine bitartrate ("cysteamine") in patients diagnosed with non-alcoholic steatohepatitis ("NASH").
Raptor" or the "Company") (BULLETIN BOARD: RPTP) , today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease.
Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's").
Raptor" or the "Company") (BULLETIN BOARD: RPTP) , today announced the completion of patient enrollment in its Phase 2a open-label clinical trial to evaluate cysteamine bitartrate ("cysteamine") in patients diagnosed with non-alcoholic steatohepatitis ("NASH").
Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the initiation of patient dosing in a Phase 2a clinical trial, in collaboration with the University of California, San Diego ("UCSD"), to evaluate cysteamine bitartrate ("cysteamine") in adolescents diagnosed with Non-alcoholic Steatohepatitis ("NASH").
Raptor" or the "Company") (BULLETIN BOARD: RPTP) , today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's").
Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the execution of a collaboration agreement (the "Agreement") with the University of California, San Diego ("UCSD") to include a Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate ("Cysteamine") in adolescents diagnosed with Non-Alcoholic Steatohepatitis ("NASH").
Raptor" or the "Company") (BULLETIN BOARD: RPTP) , today announced the initiation of patient dosing in a Phase 2a clinical trial, in collaboration with the University of California, San Diego ("UCSD"), to evaluate cysteamine bitartrate ("cysteamine") in adolescents diagnosed with Non-alcoholic Steatohepatitis ("NASH").